Trial reportOphthalmology2026
Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial.
Trial report in Ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non-Infectious Uveitis: A Systematic Review With Pairwise and Network Meta-Analyses.Pharmacotherapy · 2026Pooled it
- Biological and Targeted Therapy in Non-Infectious Uveitis: Current Evidence and Future Perspectives.Life (Basel, Switzerland) · 2026Review
- IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?Journal of clinical medicine · 2026Review
- Comparative long-term outcomes of conventional immunomodulatory therapy, biologic agents, and combination therapy in chronic uveitis.Journal of ophthalmic inflammation and infection · 2026Article
- The ADJUST trial and its implications for biologic discontinuation in juvenile idiopathic arthritis-associated uveitis.Eye (London, England) · 2026Article
- Gut microbiota and uveitis: exploring novel mechanisms of inflammatory ocular diseases via the gut-eye axis.Frontiers in microbiology · 2026Review
- Emerging therapeutic targets in non-infectious uveitis and scleritis.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposePatients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis typically are treated with oral corticosteroids and immunosuppressive agents, such as antimetabolites and calcineurin inhibitors. Goals of treatment include suppression of ocular inflammation (inactive disease) and reduction of oral corticosteroids to a prednisone dosage of ≤7.5 mg/day (corticosteroid sparing) or, if possible, discontinuation of prednisone. The anti-tumor necrosis factor monoclonal antibody adalimumab also is used to treat these diseases, but its comparative effectiveness versus conventional agents is unknown. The purpose of this trial was to compare the effectiveness of adalimumab treatment with that of conventional immunosuppressive drugs for uveitis.
designRandomized, unmasked, comparative effectiveness trial conducted at uveitis clinics at academic medical centers and private practices in the United States and internationally.
participantsPatients with active or recently active noninfectious intermediate uveitis, posterior uveitis, or panuveitis needing immunosuppression.
methodsAdalimumab versus conventional immunosuppressive drugs (antimetabolites, calcineurin inhibitors, or both).
main outcome measuresThe primary outcome was successful corticosteroid sparing, defined as inactive uveitis at a prednisone dosage of ≤7.5 mg/day (or its equivalent) for 2 consecutive study visits ≥28 days apart at 6 months. Other outcomes included successful corticosteroid sparing at 1 year and successful corticosteroid discontinuation, defined as inactive uveitis and no oral corticosteroid therapy for 2 consecutive study visits ≥28 days apart.
resultsTwo hundred twenty-seven participants were randomized to either adalimumab (n = 114) or conventional immunosuppression (n = 113). By 6 months of follow-up, successful corticosteroid sparing occurred in 69% of participants assigned to adalimumab versus 54% assigned to conventional immunosuppression (odds ratio [OR], 1.86; 95% confidence interval [CI], 1.06-3.25; P = 0.029) and by 12 months in 86% of participants assigned to adalimumab versus 77% assigned to conventional immunosuppression (OR, 1.89; 95% CI, 0.93-3.83; P = 0.077). By 12 months, successful corticosteroid discontinuation occurred in 55% of participants assigned to adalimumab versus 40% assigned to conventional immunosuppression (OR, 1.85; 95% CI, 1.06-3.19; P = 0.028).
conclusionsFor patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis requiring immunosuppression, adalimumab treatment resulted in a greater proportion of participants with successful corticosteroid sparing at 6 months and successful corticosteroid discontinuation at 12 months compared with treatment with antimetabolites or calcineurin inhibitors. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.